Rapid increase in erythropoiesis-stimulating agent resistance is a risk factor for poor renal prognosis in patients with chronic kidney disease pre-dialysis: A BRIGHTEN study sub-analysis.

ABSTRACT: Erythropoiesis-stimulating agent (ESA) resistance is reported in approximately 10% of patients on hemodialysis and is a risk factor for mortality. The BRIGHTEN study conducted on 1,724 non-dialysis patients with chronic kidney disease (CKD) reported an ESA resistance prevalence of 13.3% and was associated with a risk factor for poor cardiovascular and renal prognoses. ESA resistance at 12 weeks after ESA administration can also indicate renal prognoses; however, a single-point estimate is insufficient because ESA resistance increases with CKD progression. We used the BRIGHTEN data for a sub-analysis and found that the ESA resistance index (ERI) (darbepoetin alpha dose/hemoglobin level) transition pattern might be more appropriate for predicting renal prognoses than an initial single-point

SUBMITTER: Kawamoto S 

PROVIDER: S-EPMC12637981 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature